ABIVAX

Company Description

---

Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer.

As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (obefazimod) as well as liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.

Headquarters

---

5 Rue de la Baume, 75008 Paris – France

Shares outstanding

---

16,740,135

IPO

---

June 26, 2015

Stock exchange(s)

---

Euronext Paris